The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Official Title: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Study ID: NCT03679767
Brief Summary: The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
California Cancer Associates for Research and Excellence, Inc., Fresno, California, United States
California Cancer Associates for Research and Excellence, Fresno, California, United States
California Cancer Associates for Research and Excellence, Inc., San Marcos, California, United States
St Joseph Heritage Healthcare, Santa Rosa, California, United States
St. Joseph Health Medical Group - Annadel Medical Group, Santa Rosa, California, United States
Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, United States
Christiana Care Helen F. Graham Cancer Center, Newark, Delaware, United States
Rcca Md, Llc, Bethesda, Maryland, United States
VA New Jersey Health Care System, East Orange, New Jersey, United States
New York Oncology Hematology - Albany, Albany, New York, United States
Kaiser Permanente, Portland, Oregon, United States
Texas Oncology Surgical Specialists - Austin Central, Austin, Texas, United States
Coastal Bend Cancer Center, Corpus Christi, Texas, United States
AIM Trials, LLC, Plano, Texas, United States
Texas Oncology - San Antonio Northeast, San Antonio, Texas, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., The Woodlands, Texas, United States
Texas Oncology - Waco, Waco, Texas, United States
Oncology & Hematology Associates of Southwest Virginia, Inc., Wytheville, Virginia, United States
LKH Graz, Graz, , Austria
Medizinische Universitat Innsbruck, Innsbruck, , Austria
Ordensklinikum, Linz, , Austria
Universitatsklinikum St. Polten, St. Polten, , Austria
Institut Bergonié, Bordeaux, , France
Institut Paoli Calmettes, Marseille, , France
CEPCM / CHU Timone, Marseille, , France
Georges Pompidou European Hospital, Paris, , France
Hopitaux Universitaires De Strasbourg, Strasbourg, , France
BAZ County Hospital, Miskolc, , Hungary
Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok, , Hungary
Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, , Italy
ASST Istituti Ospitalieri, Cremona, , Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, , Italy
Istituto Nazionale Tumori Regina Elena, Rome, , Italy
Azienda Ospedaliera Universitaria Senese, Siena, , Italy
Centrum Onkologii- Instytut im Marii Skłodowskiej Curie, Warszawa, Mazowieckie, Poland
Med-Polonia Sp. z o. o., Poznan, Wielkopolskie, Poland
Specjalistyczna Praktyka Lekarska, Lublin, , Poland
BioVirtus Research Site, Otwock, , Poland
Centrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania
Oncolab SRL, Craiova, Dolj, Romania
Medisprof SRL, Cluj-Napoca, , Romania
Clinical Emergency Hospital of Constanta, Constanta, , Romania
Center of Oncology Euroclinic, Iasi, , Romania
Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, , Romania
Oncocenter - Oncologie Clinica SRL, Timisoara, , Romania
Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain
Centro Oncologico De Galicia, A Coruna, , Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
MD Anderson Cancer Center Madrid, Madrid, , Spain
Hospital Puerta De Hierro, Majadahonda, , Spain
Hospital Universitari La Fe, Valencia, , Spain
Name: Mark Cornfeld, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR